These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs. Fülöp T; Kozma GT; Vashegyi I; Mészáros T; Rosivall L; Urbanics R; Storm G; Metselaar JM; Szebeni J J Control Release; 2019 Sep; 309():333-338. PubMed ID: 31295544 [TBL] [Abstract][Full Text] [Related]
26. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin. Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Kikuchi H; Ishihara H Int J Pharm; 2014 Dec; 476(1-2):205-12. PubMed ID: 25280884 [TBL] [Abstract][Full Text] [Related]
27. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions. Kozma GT; Mészáros T; Vashegyi I; Fülöp T; Örfi E; Dézsi L; Rosivall L; Bavli Y; Urbanics R; Mollnes TE; Barenholz Y; Szebeni J ACS Nano; 2019 Aug; 13(8):9315-9324. PubMed ID: 31348638 [TBL] [Abstract][Full Text] [Related]
28. Pegylated liposomal doxorubicin in ovarian cancer. Green AE; Rose PG Int J Nanomedicine; 2006; 1(3):229-39. PubMed ID: 17717964 [TBL] [Abstract][Full Text] [Related]
29. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Szebeni J; Fontana JL; Wassef NM; Mongan PD; Morse DS; Dobbins DE; Stahl GL; Bünger R; Alving CR Circulation; 1999 May; 99(17):2302-9. PubMed ID: 10226097 [TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers. Merkel OM; Urbanics R; Bedocs P; Rozsnyay Z; Rosivall L; Toth M; Kissel T; Szebeni J Biomaterials; 2011 Jul; 32(21):4936-42. PubMed ID: 21459440 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Vail DM; Chun R; Thamm DH; Garrett LD; Cooley AJ; Obradovich JE Clin Cancer Res; 1998 Jun; 4(6):1567-71. PubMed ID: 9626479 [TBL] [Abstract][Full Text] [Related]
32. Liposomal doxorubicin: the good, the bad and the not-so-ugly. Szebeni J; Fülöp T; Dézsi L; Metselaar B; Storm G J Drug Target; 2016 Nov; 24(9):765-767. PubMed ID: 27030293 [TBL] [Abstract][Full Text] [Related]
33. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase. Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Yang H J Pharm Pharmacol; 2008 Dec; 60(12):1651-7. PubMed ID: 19000370 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Skubitz KM; Skubitz AP Anticancer Drugs; 1998 Jan; 9(1):45-50. PubMed ID: 9491791 [TBL] [Abstract][Full Text] [Related]
35. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Chanan-Khan A; Szebeni J; Savay S; Liebes L; Rafique NM; Alving CR; Muggia FM Ann Oncol; 2003 Sep; 14(9):1430-7. PubMed ID: 12954584 [TBL] [Abstract][Full Text] [Related]